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ABSTRACT 
Equipment sharing among people who inject drugs (PWID) is a key risk factor in infection by 
hepatitis C virus (HCV). Both the effectiveness and cost-effectiveness of interventions aimed 
at reducing HCV transmission in this population (such as opioid substitution therapy, needle 
exchange programs or improved treatment) are difficult to evaluate using field surveys. 
Ethical issues and complicated access to the PWID population make it difficult to gather 
epidemiological data. In this context, mathematical modelling of HCV transmission is a 
useful alternative for comparing the cost and effectiveness of various interventions. Several 
models have been developed in the past few years. They are often based on strong hypotheses 
concerning the population structure. This review presents compartmental and individual-
based models in order to underline their strengths and limits in the context of HCV infection 
among PWID. The final section discusses the main results of the papers. 
 
KEYWORDS 
Antiviral treatment; dynamic modelling; harm reduction policies; hepatitis C; injecting drug 
users   
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INTRODUCTION 
In high income countries, people who inject drugs (PWID) are the main population at risk of 
infection with hepatitis C virus (HCV), with a seroprevalence ranging between 15% and 90% 
(1). The risk of HCV transmission is high for all drug-equipment sharing that can lead to 
blood contact: injection equipment (syringes, cotton or cups (2)), straws (3) and crack pipes 
(4). 
Risk reduction measures have been taken to reduce HIV and HCV transmission among 
PWID. These measures have focused mainly on opioid substitution treatments such as 
methadone and buprenorphine, and on needle exchange programs (5). However, other 
measures are possible. Indeed, some European countries have financed and launched 
supervised injection and needle exchange programs in prisons (6). Moreover, the landscape of 
therapy for HCV infection, where treatment was suboptimal until recently, is rapidly 
changing. More efficient and tolerable treatment strategies have become available. Previr-
containing regimens – already available – have significantly increased the chances of a 
sustained virologic response (SVR, i.e. undetectable levels of HCV for an extended period of 
time) for patients infected with genotype 1 HCV, the most prevalent HCV genotype in 
western Europe and North America among PWID (5, 7). Using these combinations, for 
patients treated for the first time, the SVR rate for genotype 1 reaches 70-75% vs. 50% for 
treatments with pegylated interferon and ribavirin (8-12). Other, more effective pan-genotypic 
drugs that are used orally and may be prescribed for a shorter duration are at advanced stages 
of development (13, 14). Given that non-viremic patients (i.e. those with a SVR) cannot 
transmit the infection (15), we are now considering the use of treatment as a means of 
preventing transmission of HCV in this population (« treatment as prevention »).  
However, the implementation of harm reduction programs (HRP), like needle exchange 
programs, and the use of these new treatments to avoid transmission imply additional costs. 
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For optimal use of available resources, it is important to evaluate the effectiveness and cost-
effectiveness of these strategies. For this purpose, clinical studies and traditional 
epidemiological studies such as historical comparisons, cohorts and/or case-control studies 
encounter problems of feasibility, cost and time, especially in the PWID population, which is 
difficult to reach. Mathematical modeling is an alternative; indeed, it enables an estimation of 
the efficiency and cost of multiple strategies of harm reduction, screening and treatment 
effects upon HCV transmission within a short period of time. The main goal of the present 
article is to review mathematical models used to simulate transmission of HCV among PWID, 
and to evaluate their pros and cons. 
The first section briefly summarizes the corpus of papers found. The second describes 
compartmental models and their properties. The third section describes individual-based 
models and their properties. The final section presents results obtained and recommendations 
for public health policies. 
 
SEARCH STRATEGY AND SELECTION CRITERIA 
The aim of the review was to identify dynamic mathematical models used for transmission of 
HCV among PWID in the literature and to evaluate their strengths and limits. Eligible studies 
had to satisfy two conditions: 1) describe a dynamic mathematical model for transmission of 
HCV; and 2) study a population of PWID. In accordance with Cochrane collaboration 
guidelines (16), we conducted our search in the Medline database using the keywords 
mathematical, model, hepatitis C and drug user and variations of these words. Our review 
takes into account the bibliographies of all identified publications and includes all items found 
until June 2014.  
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RESULTS 
Of 214 articles identified, we examined 57 of them in details and keep 32 articles that fulfilled 
the above criteria (see Figure 1 for details about the reasons for exclusion). We added 5 
articles coming from other sources, given a total of 37 original articles (17-53). The modeled 
populations were mainly from the United Kingdom (17-22, 26, 35, 36, 43, 45-48), Australia 
(27, 31, 33, 43, 50, 51) and USA (30, 37-39, 49, 52). Two articles involved analyses in 
developing countries: that of Durier et al. (25) studied a population of PWID in Vietnam, 
while Vickerman et al. (24) examined a population of PWID in Pakistan.  
The main objectives of these studies were: (i) to present a model of transmission of HCV and 
provide analytical results concerning the mathematical properties of the model model (28, 35-
39); (ii) to evaluate the impact of HRP (on the chronic/antibody prevalence, incidence, 
number of infections and quality adjusted life years (QALYs) gained) (21, 22, 24-26, 29, 33, 
36-41, 50, 51), (iii) to compare epidemics dynamic of HCV and HIV infections  (1, 23, 24, 
28, 33, 40-42, 44, 45); (iv) to evaluate the impact of treatment of HCV infection on 
transmission (17-19, 25, 34, 43, 49, 50) and cost (20, 43); and (v) to evaluate the impact of 
potential HCV vaccination strategy (30, 32, 51). Objectives and main results of these articles 
are detailed in Table 1. 
Mathematical models used in the articles were divided into two categories: compartmental 
models and individual-based (or agent-based) models (IBMs). The assumptions underlying 
the two models and their strengths and weaknesses are presented in the following sections  
In addition, we distinguished two approaches in these articles: stochastic or deterministic. In 
the stochastic approach, the epidemic is considered as a chain of events (infections, recovery, 
etc.) occurring at random times among individuals. Thus, this approach takes into account the 
randomness of durations of the different health stages in the population. At each event, the 
transition that occurs is determined by probabilities induced by the global transition rates. 
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When dealing with large populations, averaging of randomness leads to deterministic 
evolutions that can be described by ordinary differential equations (54). For further 
explanation about the advantages and weakness of these two approaches, the reader can refer 
to (55).  
 
COMPARTMENTAL MODELS 
Description 
Compartmental models were the most frequently used class of models for HCV epidemic 
simulation among PWID with 31 of the 37 articles in our review (see Table 1). They 
considered transmission of HCV infection at the macroscopic scale, dividing the population 
into compartments corresponding to different states of the infection process: susceptible, 
infectious, recovered, etc. (54, 56). Transitions from one state to another were based on rates 
that could be time dependent. 
For instance, Figure 2 presents a model we have recently developed for HCV transmission in 
PWID (57). The population is distributed in eight compartments associated with HCV 
infection and care status. Susceptible PWID are separated into two categories: new and 
experienced injectors, as recently initiated injectors are at higher risk of infection (58). When 
infected, they progress to acute hepatitis that can lead either to spontaneous recovery (and 
PWID become susceptible again) or to undiagnosed chronic hepatitis C. Infected patients 
could be diagnosed, and progress to diagnosed & non-linked to care hepatitis C stages. They 
are then linked to care and lost to follow-up, or treated. When treated, patients may respond to 
treatment and return to a susceptible state, or not respond and progress to a non-SVR state. 
Transitions between different compartments or states are governed by annual transition rates 
that may be time-dependent. For example, rates of infection depend on the current proportion 
of infected PWID in the population. 
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Other published models include more compartments or less compartments according to the 
objectives and available data. The most parsimonious models include only two compartments: 
susceptible and infectious (28, 33, 37-39). Some authors included in their model the uncertain 
immunization (59) of previously infected PWID against re-infection (18, 19, 21, 24, 35, 45). 
Durier et al. differentiated symptomatic and asymptomatic acute infection (25). Esposito et al. 
and Cipriano et al. added compartments to model the use of intravenous drugs as an epidemic 
linked to the HCV epidemic (29). Martin et al. took into account the possibility of 
imprisonment. Additional compartments can allow including substitution therapies (27, 47, 
48). Finally, in order to estimate the cost of the infection or the consequences of HCV 
infection on the population’s health, some authors included additional compartments of 
natural history of chronic hepatitis C (20, 52). 
  
Strengths and limits 
Compartmental models have the advantage of not needing intensive computation time. In 
large populations, the trajectory of the epidemics can be described by a system of ordinary 
differential equations (55). However, they are based on two important hypotheses. 
First, the population of a compartment is supposed to be homogeneous. The only 
characteristic of an individual is the compartment in which he/she is located. Thus, parameters 
that define an individual are parameters that are derived from the overall population; they can 
be easily interpreted in term of epidemiology and obtained from epidemiological studies. This 
is not necessarily the case for individual-based models (IBMs; see below). For example, the 
infection rate represents the force of infection in the population, for which estimations are 
available for HCV among PWID (58). However, PWID population is highly heterogeneous. 
There is a variability of individual characteristics and behaviors, which can impact the risk of 
infection by HCV or HCV-infected patients care. Indeed, the high variations of infection risk 
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among PWID are due to differences in injection frequency, numbers of syringe sharing and 
number of sharing partners (60). Moreover, response rates to HCV treatment are different 
according to HCV genotypes. With a pegylated interferon + ribavirin regimen, SVR is around 
75 for naïve patients infected with genotypes 2 or 3; and around 50% for naïve patients 
infected with genotype 1 (8-12). One may hypothesize that this could lead to the selection of 
hard-to-treat genotypes, and thus to a large proportion of prevalent cases infected with 
genotype 1. For simplicity, most of the published models do not differentiate genotypes; and 
consider only an average duration of treatment and SVR rate in the population. Cipriano et al. 
study represents an exception, differentiating genotypes 1-4 of genotypes 2-3 (52). 
Nevertheless, with the availability of highly effective pan-genotypic anti-HCV regimens not 
differentiating genotypes will no more be a problem. Some other characteristics are known to 
impact HCV transmission or treatment success: time since first injection, as the risk of 
transmission is higher in recent frequent injectors (58); substitution therapy with reduced risk 
of transmission from those who receive substitution (61); gender, as the spontaneous recovery 
rate is higher in women (62); HIV-HCV co-infection, associated with lower treatment success 
(63), imprisonment, as a history of injection in prison increase the risk of infection (64), and 
even genetic characteristics, with the IL28B polymorphism impacting the treatment response 
(65). Stratification of the population into different risk groups is a solution for relaxing the 
hypothesis of homogeneity of PWID (21-25, 27, 29, 36, 40-45). Vickerman et al. considered 
3 levels of risk corresponding to no syringe sharing, low- and high-frequency syringe sharing 
(21-23). Corson et al. structured their population by experience at injection: recent injectors 
were more likely to be infected than experienced injectors (36). Zeiler et al. aimed at 
estimating the impact of methadone maintenance programs and structured their population by 
methadone intake (27). However, stratification of the population is equivalent to introducing 
different compartments for each group, which can turn the model highly complex. For 
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example, the model in Cipriano et al. has 756 compartments (52). Such models imply to 
estimate a lot of parameters, and data about PWID are often scarce due to the difficulty to 
reach this population by epidemiological studies.  
Secondly, the infection rate is often based upon the hypothesis that the population is totally 
mixed, in the sense that each susceptible individual can potentially be infected by any 
infectious person: in classical models, the infection rate per susceptible individual βI(t) 
increases with the number of infected persons in the population. This hypothesis seems to be 
poorly suited for describing infectious contacts with a blood-borne pathogen among PWID. 
Indeed, it has been shown that PWID share their injection material with a restricted group of 
injection partners. Wylie et al. found that PWID in Canada have few other PWID in their 
individual network: a median of 3.5 was found for a period of 30 days (60). Brewer et al. 
found a mean number of 18 injecting partners (not necessarily involving syringe/needle 
sharing) during a 12-month period of presumed HCV infection among HCV-positive PWID 
in Seattle (66). Sacks-Davis et al. reported, in Melbourne, a median number of 3 injection 
partners/IDU, with a median duration of 3 years for a partnership, and they found that HCV 
phylogeny was associated with the injection network (67). These results suggest that the 
number of potential infectious contacts is restricted to a small group for each infected PWID, 
which slows the transmission of the virus in the population. However, they are based on a 
snapshot, and give no indication at a lifetime scale. In addition, Hahn et al. suggest that 
because of the high number of injecting partners the turnover of the injecting partners may be 
sufficiently high to consider that a totally mixed population is a valid hypothesis (30).  An 
alternative approach chosen by several authors to relax this hypothesis in compartmental 
models is to include assortative mixing: they varied the mixing of the different risk groups. 
Fourteen articles in the present review among the 31 compartmental models took into account 
assortative mixing in the population according to risk groups (21-24, 40, 42-45, 48), 
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substitution therapies (25, 27), experience as injector (46) or age (47). However, this solution 
does not enable taking into account small subgroups at the individual or community scale 
(injecting partners groups), but only groups at a population scale.  
 
INDIVIDUAL-BASED MODELS 
Description 
In 2001, Pollack already underlined that, while a simple model enables obtaining several 
important results, a homogeneous totally mixed population implies biases in the estimation of 
the effectiveness of HRP and does not enable to assess effectiveness of targeting interventions 
(37-39). A possibility to overcome these hypotheses is the use of individual-based models 
(IBMs). IBMs simulate the patients’ trajectories at an individual level, so that we can attach to 
each of them a specific set of characteristics (age, gender, alcohol consumption, frequency of 
risk-taking, etc.), on which the different transition rates may depend (68-70).  
For HCV epidemic modeling among PWID, only a few authors have used IBMs. Mather et al. 
considered a model taking into account isolated groups of individuals with possible 
immunization of individuals (51). De Vos et al. developed a model taking into account HCV 
and HIV infections in which mortality and transmission of viruses were based on individual 
characteristics: age, time since the first injection and time since infection (41). Hahn et al. 
developed an IBM to take into account different behaviors and levels of risk exposure in the 
population (30). The authors distinguished two practices at risk: risky needle sharing (RNS) 
and ancillary equipment sharing (AES); the probability of infection varied based on the level 
of risk exposure (corresponding to frequencies of RNS and AES) and HCV stage of the 
partner (higher infectivity during acute infection). Hutchinson et al. and Rolls et al. presented 
IBMs that took into account the social network of the population (see below) (26, 31, 50). 
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Modeling contact network 
The network of contacts can be represented by a graph, i.e. a set of vertices representing 
individuals and interconnected by a set of edges representing potentially infectious contacts 
between them (see example Figure 3).  
Various network models have been described in the literature ((71) and therein). The choice 
of these models depends on the expected characteristics of the network. Some simple graphs 
which are easily implemented have unrealistic characteristics and neglect major aspects of the 
network structure, when focusing on the case of the PWID social networks. They are often 
based only on individual information like the degree, i.e. the number of individuals in contact 
with that person in the network. For example, the configuration model is constructed from a 
chosen degree distribution (72, 73). Following this distribution, a degree is attributed to each 
member of the population, by giving  half-edges to each individual. The half-edges is then 
connected to another at random.  
Local information, for example the degree, which can be obtained relatively easily using 
traditional epidemiological studies, by requesting the number of sharing partners or injection 
partners for each participant. More complex models such as intersection graph models (74, 
75), household graph models (76, 77) and stochastic block models (78) have been proposed to 
reproduce characteristics of real networks, such as transitivity. The transitivity reflects the 
preferential association of two persons if they have a common relationship: two individuals 
are more likely to be friends if they have a common friend. In terms of the graph, this results 
in a large number of triangles in the network. These models are difficult to calibrate due to the 
need for information on the global topography of the network. We may have to determine the 
size of the communities and the probability of connection between individuals of the same 
group and between individuals of different groups, etc. We cannot obtain such information 
through traditional studies: independent sampling of the individuals only provides information 
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about the neighborhood of the participants. To catch the global topography of the network, we 
must use specific methodologies such as chain-referral sampling used by Friedman et al. to 
study the network of a population of PWID in New York City (79). In such surveys, new 
participants are recruited by previous participants among partners. The final result is a 
subgraph of the population’s network. 
In the case of HCV in PWID, Hutchinson et al. used a configuration model (26). The number 
of partners for the PWID was generated by a geometric probability distribution with 
parameter 𝑝 ∈ (0,1), i.e.  𝑃(𝑋𝑖 = 𝑘) = (1 − 𝑝)
𝑘−1𝑝.  This distribution was suggested by data 
on the distribution of degree in a population of PWID in Glasgow at the beginning of the 90’s. 
Rolls et al. applied an IBM to a real network of 258 PWID in Melbourne, obtained by using 
chain-referral sampling (31). This approach enabled the authors to obtain a very realistic 
network structure (80). However, it was limited to a small sample due to the difficulty in 
tracing the contact network of different PWID. They compared results of their model with the 
empirical network and with a fully connected network (equivalent to the totally mixed 
hypothesis of compartmental models). They found that time to infection was shorter in a fully 
connected network, indicating that the structure of the network highly impacts output in HCV 
transmission. In more recent papers, they calibrated an exponential random graph model 
(ERGM) on these data (50, 80). ERGMs are statistical models aiming to reproduce some 
characteristics of the initial network (i.e.; the number of edges, isolates, triangles, in 
particular). The ERGM used by Rolls et al. is based on the research of homophily in the 
network, which is the preferential attachment between PWID due to their similar 
characteristics: location, gender, age, frequency of drug use. This is an important part of the 
social component of the network. 
Another research question in PWID is the dynamic of the network. Indeed, in a real 
population of PWID, the contact pattern may change: the identities of the different sharing 
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partners change over time as relationships between PWID evolve (26). A static network 
model, with identities of sharing partners fixed over time, may miss a crucial aspect of the 
social network. It may be a good approximation if contacts change at a slow rate relative to 
epidemic dynamics. Inversely, if contacts change quickly relatively to the spread of the 
disease, then the dynamic effects cannot be neglected (81). For HIV epidemics on sexual 
contact network the dynamic of the sexual partnership network has been proved to impact the 
epidemic trajectory (82-84). For HCV in PWID, it is an open question. Only Hutchinson et al. 
have used a dynamic network model with a turnover of sharing partners for each individual 
each year. Two variants of turnover were tested: a turnover totally at random, and a turnover 
with some stability in injecting partners groups, with few differences between the results in 
these two settings. These dynamic models are however not be supported by data. 
From another point of view, Hahn et al. suggest that because of a high dynamic in the contact 
network, the population can be modelled as static and totally mixed (30). There is no evidence 
about this affirmation because it is only supported by the high number of reported injecting 
partners.  
Further investigations should be conducted to clarify the necessity of dynamic models. Of 
note Sacks-Davis et al. reported, in Melbourne, a median number of 3 injection partners/IDU, 
with a median duration of 3 years for a partnership (67), suggesting a relative stability of the 
network.  
 
MAIN RESULTS OF THE REVIEWED PAPERS 
The objectives of articles on HCV transmission among PWID are numerous. However, 
important results consistently emerge. 
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Vaccination 
The potential effect of a vaccination against HCV was evaluated in three articles. Mather et 
al. showed that even immunizing half the population with a vaccine which has an 80% 
efficacy slows the spread of the infection in an Australian PWID population (51). For Dontwi 
et al., potential vaccination must be carried out early and should cover a large portion of the 
population (>80%) so as to reduce the force of infection (32). Hahn et al. tested scenarios that 
specifically target certain individuals in a population of PWID in USA (30). They found that 
vaccination is most effective when it targets high-risk individuals (with more frequent risk-
taking) without taking into account serological status, or when targeting HCV-seronegative 
persons.  
 
Harm reduction policies 
The first author to take an interest in estimating the impact of harm reduction by a model was 
Pollack, who examined a needle exchange program in USA (37-39). His results suggested 
that, while such a program may have an impact and could potentially eradicate the infection, 
the cost quickly becomes prohibitive for highly transmissible infections like HCV (>250.000$ 
per averted infection). However, he suggested that the association of this program with a 
methadone maintenance therapy strategy would reduce transmission of the virus in the 
population and, as a consequence, decrease the cost of needle exchange programs. He stated 
that, for HCV, a combination of different strategies is necessary to impact HCV transmission 
(39). However, he underlined that the absence of heterogeneous behavior and the totally-
mixed hypothesis could impact the results. Vickerman et al. also found that widespread 
sustained coverage of syringe exchange in the population (reduction > 40% of needle/syringe 
sharing) is necessary in order to obtain a significant reduction in prevalence after 10 years in 
Rawalpindi, Pakistan (24). 
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Hutchinson et al. estimated the impact of HRP on HCV transmission, by varying the 
percentage of PWID who had shared per year, the mean number of needle/sharing partners 
and the percentage of injecting episodes (26). For the period 1988-2000, they estimated that 
4,500 infections would have been prevented in Glasgow with HRP. They also found that 
reducing the mean number of partners to one (versus between 2 and 3 partners in the baseline 
scenario) might prevent 5,300 infections during the same period (with this measure alone). 
Moreover, wide and sustained decrease of needle/syringe sharing would be necessary to have 
a similar impact on transmission (5,200 infections prevented): only 11% to 20% of PWID 
should be able to share a needle/syringe during that period.  
Some authors suggested that the target of these interventions could be optimized. Vickerman 
et al. suggested targeting recent injectors not reached by HRP and not already infected in UK 
to reduce syringe sharing in this particular part of the population (21). They found that a 
significant reduction in seroprevalence could occur among recent PWID (<4 years) with a 
reduction in sharing frequency <25%, although among experienced PWID (>8 years), similar 
results would only occur with a reduction >50%. Similarly, Corson et al. suggested that 
interventions in Scotland are most efficient during the first 5 years of the injecting career (36). 
Esposito et al. in Italy showed a delay of one year between the peak of drug use and the peak 
of prevalence for HCV, suggesting also that interventions should occur early during the 
injecting drug career to impact HCV transmission (29).  
In the context of limited resources, De Vos et al. suggested that PWID at low risk (i.e. less 
frequent syringe sharing) should be targets for HRP (aiming at reducing syringe sharing rate) 
so as to maximize their impact (41). They questioned also whether the decrease in HCV 
incidence in Amsterdam since 1990 was related to HRP. They found that realistic results with 
their model could only be obtained in the presence of HRP, but demographic changes in the 
PWID population primarily explained the decrease. 
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Impact of harm reduction strategies on HIV and HCV infection among PWID  
The impact of HRP upon HIV transmission is much stronger than upon HCV transmission 
(33). Coutin et al. and Pollack showed that the higher infectivity of HCV compared to HIV 
implied that greater effort is needed to significantly impact HCV transmission in their model 
(28, 39). Vickerman et al. estimated that reducing the injection risk by 30% would result in a 
reduction in the incidence/seroprevalence of 50%/28% for HIV and 37%/10% for HCV after 
5 years in a population of PWID in UK (23). De Vos et al. found similar results (42). Murray 
et al. estimated the number of annual injection partners below which infections by material 
sharing were less likely to occur than infections by other sources to be 17 partners/year for 
HIV and 3 partners/year for HCV in an Australian setting (33). They estimated the actual 
number of partner to be intermediate (≈6), which explains the success obtained against HIV 
and more questionable results for HCV. Bayoumi et al. estimated the effectiveness and cost-
effectiveness of supervised injection facilities in Vancouver (53). Their results suggest 
between $14 and $18 million gained and between 920 and 1175 life-years saved after 10 
years. However, the authors underlined that the cost saving is mainly due to HIV infections 
averted. 
 
HCV treatment 
The impact of HCV treatment on transmission is considered to be effective despite the risk of 
reinfection (17, 19, 25, 34). Some authors recommended specific targets and application 
modalities. Zeiler et al. studied the impact of HCV treatment in Australia, taking into account 
methadone maintenance therapy (27). The main concern of that paper was to determine the 
optimal distribution of treatment in the population. The results suggested treating active 
PWID rather than PWID under methadone maintenance therapy, with the hypothesis of equal 
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adherence to treatment in the two groups. The conclusion would be reversed only if adherence 
by active PWID was <44% of that of PWID under methadone maintenance therapy. Also in 
Australia, Hellard et al. found that even a modest annual rate of treatment (25/1,000 PWID) 
could have an impact on long-term HCV chronic prevalence (50% decrease after 30 
years)(34). Martin et al. found similar results for the United Kingdom: for a baseline chronic 
prevalence of 20%, 40% and 60%, an annual treatment rate of 10/1,000 PWID would achieve 
a reduction in chronic prevalence of 31%, 13% and 7%, respectively after 10 years (19). 
Durier et al., in Vietnam (with few HRP) found similar results (25). They estimated a strategy 
of treatment as prevention, and suggested treating early (during the first year) to avoid a 
maximum of infections.  
Martin et al. estimated the cost-effectiveness of HCV treatment in the United Kingdom (20). 
Their results showed that treating active PWID and ex- or non-PWID was cost-effective, but 
for a chronic prevalence below 60%; treating active PWID was more cost-effective because of 
avoided re-infection. This result remained valid even with a SVR rate in active PWID that 
was 50% lower than that of ex- or non-PWID (which may reflect lower adherence to 
treatment). 
Martin et al. estimated the impact of a coming direct-acting antiviral, with treatment of 
shorter duration and with a higher tolerability (43). They compared efficiency and cost in 
three different geographic settings: Edinburgh, Melbourne and Vancouver. The study showed 
that halving the chronic prevalence after 15 years would be extremely expensive, particularly 
in Melbourne and Vancouver (around $50 million) where the chronic prevalence is high.  
Finally, in Australia, Rolls et al. targeted infected individual for treatment initiation according 
to their neighbors on the social network, with strategies including random treatment delivery, 
priority by node degree, treatment of the primary contacts of infected nodes, treatment of 
primary and secondary contacts of infected nodes, and treatment of treatment of the primary 
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contact of uninfected nodes (50). They found that strategies including the treatment of 
primary and secondary contacts of some infected PWID randomly chosen for treatment 
(“ring” treatment) are the most effective strategies for a similar number of treatment starts. 
 
CONCLUSION 
To date, several different models have been used to study transmission of HCV among PWID. 
Most of them were built to answer a specific question taking into account only the 
characteristics of PWID that pertained to that question, and thus averaging the non-relevant 
characteristics. Specific points seem to recurrently emerge in these articles: the long-term 
effects of HRP and HCV treatment on HCV prevalence, the advantage of specifically 
targeting more risky PWID (recent injectors, active PWID or PWID not on methadone 
maintenance therapy), and the importance of implementing these measures early (at the 
beginning of the injecting career for HRP, and at the beginning of chronic infection for 
treatment). However, more general models are needed to compare a combination of different 
strategies of risk reduction (needle exchange programs, substitution therapy), screening and 
treatment (efficacy of new treatments). Mathematical modeling can enable evaluating the cost 
associated with those different strategies and guiding optimal resource allocation.  
Most models are compartmental and rely on strong assumptions. An individual-based 
approach could be an interesting alternative allowing, for example, to estimate the impact of 
strategies based on PWID characteristics and social networks. The most advanced works on 
this topic are that of Rolls et al. showing that treatment strategies based on the social network 
have more impact on transmission than a random treatment distribution (50). But such studies 
still few in numbers. One of the main difficulties lies in the lack of data for first calibrating 
and next to be used in the model. Data are difficult to obtain in particular regarding the risk of 
HCV transmission during an exchange, the frequency of material sharing, and social networks 
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and their dynamics over time. As pointed out by Kretzschmar et al., the construction of such 
models therefore requires multidisciplinary collaboration that includes clinical (transmission 
risk, treatment efficacy), epidemiological (current state of infection, screening, treatment), 
mathematical (modeling) and sociological (social network characteristics among PWID) 
components (85). 
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Table 1: Summary of the review 
Reference 
Country 
 
(setting) 
Objectives Model/approach Main results 
Mather et al. (51) Australia To obtain predicted outcomes of 
different scenarios of immunization 
by an hypothetical vaccine and to 
identify sensitive parameters of the 
model 
Individual-based model / stochastic 
approach 
 
The rate of spread of HCV trough an PWID 
population is not really sensitive to the initial 
prevalence, but it is sensitive to the proportion of 
groups members with whom the individual has 
contact and the probability of infection per contact 
with an infective (encouraging HRP) 
 
A hypothetical vaccine with 80% efficacy would 
have a measurable impact on the spread of the 
infection, even with moderate coverage rate 
(around 50%) 
Pollack (39) USA To assess the impact of a syringe 
exchange program on HCV so as to 
understand why it is effective for 
HIV but not for HCV in an PWID 
population 
Compartmental model/ 
deterministic differential equations 
- Analytic results (steady state 
analysis) 
Modest interventions (reduce incidence by a third) 
are only effective for hard-to-transmit infections 
(like HIV), while for HCV, with a high 
prevalence, only a massive program will have an 
impact. Moreover, for a high-prevalence setting, 
the impact will occur over the long term 
Pollack (38) USA To assess the effectiveness and 
cost-effectiveness of a syringe 
exchange program 
Compartmental model/ 
deterministic differential equations 
- Analytic results (steady-state 
analysis) 
The syringe exchange program is effective and 
cost-effective when R0 is low (2.9 for HIV), but 
becomes less effective when R0 is high (6.9 for 
HCV) and cost become prohibitive (>250.000$ 
per averted infection), which is more realistic (in 
short-term analysis). This is necessary to combine 
syringe exchange program with intervention 
aimed at decreasing the R0, such as the 
methadone maintenance program. 
26 
 
Reference 
Country 
 
(setting) 
Objectives Model/approach Main results 
Pollack (37) USA To assess biases that represent 
short-term analysis compared to a 
long-term analysis (i.e. taking into 
account changes in prevalence in 
steady-state analysis) in the 
evaluation of harm reduction 
intervention among PWID  
Compartmental model/ 
deterministic differential equations 
- Analytic results (steady-state 
analysis) 
The short-term incidence underestimates the 
effectiveness of a program of long-term syringe 
exchange if the steady-state prevalence, in the 
absence of intervention, is below 50%. 
Conversely, if it is over 50%, the short-term 
incidence overestimates effectiveness. 
Murray et al. (33) Australia To assess the impact of different 
levels of needle sharing on the 
prevalence of HIV and HCV 
among PWID  
Compartmental model/ 
deterministic differential equations 
 
The needle exchange program has less impact on 
HCV than on HIV: the number of annual injection 
partners below which infections by material 
sharing were less likely to occur than infections 
by other sources to be 17 partners/year for HIV 
and 3 partners/year for HCV 
Esposito et al. (29) Italy To present a mathematical model 
taking into account the "epidemic" 
of drug use 
Compartmental model/ 
deterministic differential equations 
 
 
HRP must be initiated early to be efficient 
 
Incidence is the best indicator of impact (delays 
are shorter than for prevalence) 
Hutchinson et al. (26) United-
Kingdom 
To model the hepatitis epidemic 
among PWID in Glasgow and 
implications for prevention 
Individual-based model on a 
simulated contact network of PWID 
/ stochastic approach 
 
 
 
 
The estimated seroprevalence in the 90s was 
lower than currently observed. This result can be 
corrected by increasing viremia during the acute 
phase, which could confirm the higher rate of 
viremia during that period. 
 
Current public health messages (not sharing 
needles) are inadequate for HCV (but effective for 
HIV). The authors propose encouraging PWID to 
share with only a small group of trusted persons 
(tested negative) and predict that by reducing the 
mean number of partners to one (vs. 2-3) 5,300 
infections could have been avoided between 1988 
and 2000  
27 
 
Reference 
Country 
 
(setting) 
Objectives Model/approach Main results 
Vickerman et al. (21) United-
Kingdom 
To assess the impact of decreased 
needle sharing on HCV 
transmission 
Compartmental model/ 
deterministic differential equations 
 
 
 
Current public health interventions aiming at 
reducing needle/syringe sharing (like 
needle/syringe exchange) should target new or 
recently initiated injectors to have an optimal 
impact. There is therefore a need to work on new 
injectors which is currently not the case. 
 
Moreover, we have to target all PWID, not just 
those with a high frequency of syringe sharing  
 
Frequency sharing must be significantly reduced 
(to 1-2 times a month) to achieve a seroprevalence 
≤ 10% 
Bayoumi et al. (53) Canada To estimate the cost-effectiveness 
of Vancouver’s supervised 
injection facility 
Compartmental model/ 
deterministic differential equations 
 
If a reduction of needle sharing is the only effet of 
the supervised injection facility: incremental net 
savings of almost $14 million and 920 life-years 
saved after 10 years. 
 
When adding an increase use of safe injection 
pratices and increased referral to methadone 
maintenance treatment: incremental net savings of 
almost $18 million and 1175 life-years saved after 
10 years. 
 
The cost saving is mainly due to HIV infections 
averted. 
Hahn et al. (30) USA To assess the impact of 
vaccinations (at different levels of 
effectiveness) on the HCV 
epidemic among PWID  
Individual-based model / stochastic 
approach 
 
 
Several scenarios of vaccination were tested: 
- randomly vaccinate the population 
- vaccinate individuals with more risky behavior 
- vaccinate individuals seronegative for HCV 
(sero-targeting) 
The third scenario is the most effective, followed 
by the second, suggesting that random vaccination 
is not a good strategy.  
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Reference 
Country 
 
(setting) 
Objectives Model/approach Main results 
Vickerman et al. (24) Pakistan To explore different hypotheses to 
explain the low prevalence of HCV 
among PWID in Rawalpindi, 
Pakistan and to estimate the impact 
of interventions 
Compartmental model/ 
deterministic differential equations 
 
 
Most syringe sharing involves low risk, because it 
concern only a small group of the users’ 
acquaintances - Existence of a small group that 
carries out high-risk sharing with strangers, in 
which the prevalence is high 
 
Predicted increase in HIV prevalence in 5-10 
years 
 
A reduction of syringe sharing > 40% could 
reduce the number of HCV/HIV infections of 
around 45% after 10 years if all PWID are 
reached 
Zeiler et al. (27) Australia To study the impact of HCV 
treatment allocation according to 
methadone taking 
Compartmental model/ 
deterministic differential equations 
 
 
Advantage of treating active users rather than 
users on methadone because of re-infection and 
high turnover of PWID on methadone. 
Dontwi et al. (32) Unspecified To assess the impact of a possible 
vaccine against HCV among PWID  
Compartmental model/ 
deterministic differential equations 
 
Potential vaccination carried out early and 
covering a large part of the population (>80%) 
would significantly reduce the force of infection 
(nearly 90%) and, ultimately, the extent of the 
epidemic 
Coutin et al. (28) Unspecified To present a mathematical model 
for the spread of a virus in an open 
population such as HCV and HIV, 
and evaluate sensitivity to 
parameters 
Compartmental model/ 
deterministic differential equations 
and stochastic approach (with 
analytical study of the convergence 
of the stochastic model to the 
deterministic model) 
 
 
 
A quarantine (i.e. isolate the population to prevent 
transmission) ensures a long-term decline in HCV 
prevalence but is impractical  
 
Increasing the number of PWID leads to a 
decrease in HCV prevalence (also impractical)  
 
The differing force of infection explain the 
different results between HIV and HCV 
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Reference 
Country 
 
(setting) 
Objectives Model/approach Main results 
Martin et al.(18) 
 
United-
Kindgom 
To study the impact of treatment on 
chronic prevalence of hepatitis C 
among PWID  
Compartmental model/ 
deterministic differential equations 
 
 
Treatment has a significant impact on 
transmission of HCV in the population despite the 
risk of reinfection 
Martin et al. (19) United-
Kindgom 
To assess the level of treatment 
required to eradicate or control the 
epidemic of hepatitis C among 
PWID  
 
Compartmental model/ 
deterministic differential equations 
 
 
Treatment has a significant impact on 
transmission of HCV in the population despite 
risk of re-infection, even for low treatment rates 
(<6% of chronically infected annually for chronic 
prevalence <40%; 10-20% for a chronic 
prevalence of 60%) 
Martin et al. (17) United-
Kindgom 
To optimize the number of 
treatments taking into account 
economic constraints  
Compartmental model/ 
deterministic differential equations 
An increase in the annual budget allocated to 
treatment would be cost-effective and would more 
rapidly reduce chronic prevalence. 
Vickerman et al. (23) Unspecified To understand the trends in HIV 
and hepatitis C seroprevalence 
among PWID in different settings 
Compartmental model/ 
deterministic differential equations 
 
Existence of a threshold for the seroprevalence of 
HCV, below which HIV prevalence is negligible 
This threshold depends on the environment 
(practices, etc.)  
 
The existence of different levels of risk groups 
and the size of these groups could explain the 
range of observed values for the prevalence of 
HIV / HCV in different settings  
 
Strategies for long-term intervention needed to 
reduce the seroprevalence of HCV  
Rolls et al. (31) Australia To propose a model of transmission 
of HCV among PWID  
Individual-based model on an 
empirical contact network of PWID 
/ stochastic approach 
Re-infection rates (20.6/100 PY) are higher than 
rates of primary infection (14.4/100 PY) 
Comparison with a fully connected graph 
(equivalent to the assumption of compartmental 
models) does not achieve this 
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Reference 
Country 
 
(setting) 
Objectives Model/approach Main results 
Event transmission rate estimated: 1% 
Cipriano et al. (52) USA To estimate the cost, effectiveness 
and cost-effectiveness of HCV and 
HIV screening (antibody and/or 
viral RNA testing) for PWID in 
OST 
Compartmental model/ 
deterministic differential equations  
 
Depending on screening frequency; adding 
HIV/HCV viral RNA testing to antibody testing 
adverts between 14.8 and 30.3 HIV infections and 
between 3.1 and 7.7 HCV infections in a 
population of 26,100 screened PWID entering in 
OST. 
 
Strategies including HCV testing have 
incremental cost-effectiveness ratio > 
$100,000/QALY gained, unless awareness of 
HCV infection status results in a decrease >5% of 
needle sharing. 
Castro Sanchez et al. (44) Italy To choose a model, identifying 
parameters to which the model is 
sensitive, fitting the model 
Compartmental model/ 
deterministic differential equations  
 
Selection of a model (from two evaluated models) 
for the force of infection; and identification of the 
number of risk groups in the population (two: low 
and high risk). 
 
The most sensitive parameters are those linked to 
syringe sharing and transmission rates in chronic 
stages of HIV and HCV infection 
Corson et al. (35) United-
Kingdom 
To present a mathematical model 
for the spread of HCV in PWID  
 
To determine the level of needle or 
syringe sharing, needle cleaning or 
needle exchange necessary for an 
eventual elimination of HCV 
Compartmental model/ 
deterministic differential equations  
 
 
The model predicts R0 < 1 and thus an eventual 
elimination of HCV infection for one of the 
following situations: 
- syringe sharing rate ≤ 54·67/year 
- needle cleaning ≥ 0·74 
- needle turnover ≥ 562·37/year 
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Reference 
Country 
 
(setting) 
Objectives Model/approach Main results 
Corson et al. (36) United-
Kingdom 
To present a mathematical model 
for the spread of HCV in PWID  
 
To study the basic reproductive 
number (R0) 
 
To study the impact of needle 
exchange 
Compartmental model/ 
deterministic differential equations  
 
 
Demonstration that with the authors model for 
R0≤1: tends toward elimination of HCV infection; 
meanwhile for R0>1: unique endemic equilibrium 
distribution. In Glasgow, R0 is estimated to be 
3.613. 
 
The interventions are more efficient if they target 
recent PWID (<5 years of injection) 
Martin et al. (20) United-
Kingdom 
To estimate the cost-effectiveness 
of HCV therapy among PWID  
 
Compartmental model/ 
deterministic differential equations 
 
 
Treating active injchronicectors and non-injectors 
is cost-effective, but if HCV chronic prevalence is 
below 60%, it is more cost-effective to treat active 
injectors 
Durier et al. (25) Vietnam To estimate the preventive effect of 
HCV therapy, methadone 
maintenance therapy and 
needle/syringes exchanges 
programs in a developing country 
context 
 
Compartmental model/ 
deterministic differential equations 
 
 
Even a low level of treatment (25%; 4 years into 
infection) has a significant impact on chronic 
prevalence (reduction >21% after 11 years) 
 
Adding needle/syringes exchanges programs and 
substitution treatment in greater numbers provides 
an additional gain 
 
Advantage of implementing measures to diagnose 
patients at earlier stages of the disease 
(“Treatment as Prevention”) 
Vickerman et al. (22) United-
Kingdom 
To investigate the impact of 
scaling-up opiate substitution 
therapy (OST) and high coverage 
needle and syringe programs on 
HCV chronic prevalence 
Compartmental model/ 
deterministic differential equations 
 
Scaling-up opiate substitution therapy and needle 
sharing programs can reduce hepatitis C chronic 
prevalence among PWID, but reductions may be 
modest and require long-term sustained 
intervention coverage: in UK, to reduce the 
chronic prevalence from 40% to less than 30% 
over 10 years needs a coverage ≥ 80%) 
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Reference 
Country 
 
(setting) 
Objectives Model/approach Main results 
Hellard et al. (34) Australia To estimate the effect of HCV 
treatment on HCV chronic 
prevalence among PWID  
Compartmental model/ 
deterministic differential equations 
Modest rates of current HCV treatment among 
PWID in Victoria, Australia (25 per 1000 PWID) 
could halve HCV  chronic prevalence in 30 years 
De Vos et al.(42) 
 
Netherlands To understand the dynamics of 
HCV and HIV infection among 
PWID  
Compartmental model/ 
deterministic differential equations 
The link between HIV and HCV prevalence is 
linked to distribution of risk, and assortativity of 
groups of risk 
 
There is a threshold for HCV prevalence below 
which HIV does not spread 
De Vos et al. (41) Netherlands To understand the effect of HRP on 
the decline in the incidence of HCV 
and HIV among PWID since 1990 
Individual-based model/ stochastic 
approach 
It is difficult to reproduce realistic behavior of 
epidemics without HRP; however, most of the 
decline can be explained by demographic changes 
De Vos et al. (40) Netherlands To estimate the effectiveness of 
targeted intervention on HIV and 
HCV among PWID  
Compartmental model/ 
deterministic differential equations 
HRP are most effective toward HIV if used in a 
high-risk group, but they must be used in a low-
risk group to impact HCV. High-risk individuals 
are already infected by HCV (the prevalence is 
high) so it is too late to prevent their infection, 
while this is not the case for HIV (low prevalence 
due to lower force of infection) 
Vickerman et al. (45) United-
Kingdom 
To understand the link between 
HIV/HCV co-infections and the 
HIV sexual transmission rate in a 
population of PWID  
Compartmental model/ 
deterministic differential equations 
To reproduce the realistic seroprevalence of HCV 
among HIV-infected PWID, it is necessary to 
include sexual transmission 
 
Moreover, the level of co-infection seems to be a 
marker of HIV sexual transmission among PWID  
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Reference 
Country 
 
(setting) 
Objectives Model/approach Main results 
Martin et al. (43) United-
Kingdom 
Australia 
Canada 
To estimate the effectiveness of 
future direct-acting antivirals on 
HCV chronic prevalence among 
PWID in 3 different settings 
(Edinburgh, Melbourne and 
Vancouver) 
Compartmental model/ 
deterministic differential equations 
The impact will be limited by current treatment 
coverage 
 
To halve the chronic prevalence of HCV within 
15 years, the cost would be high, especially in 
Melbourne and Vancouver (~$50 million), where 
the chronic prevalence is highest 
Corson et al. (46) United-
Kingdom 
To understand the role of injecting 
paraphernalia (filters, cookers and 
water) 
Compartmental model/ 
deterministic differential equations  
 
The transmission probability is estimated to be at 
least 8 times lower through paraphernalia- than 
through needle- or syringe-sharing 
 
Paraphernalia sharing is estimated to significantly 
contribute to HCV infections (62% of HCV 
infections in Scotland with current estimated 
needle/syringe sharing rates and paraphernalia 
sharing rates) 
Martin et al. (47) United-
Kingdom 
To estimate the cost-effectiveness 
of HCV case-findings for PWID 
via dried blood spot (DBS) testing 
in addiction services and prisons 
Compartmental model/ 
deterministic differential equations  
 
For a £20,000 per QALY gained willingness-to-
pay threshold, DBS testing is cost-effective in 
addiction services, but not in prison. 
 
If we increase continuity of care (proportion of 
initiated treatments/referrals that are continued 
when entering/exiting prison) to 40%, DBS 
testing become effective in prison. 
Martin et al. (48) United-
Kingdom 
To estimate the impact of 
combining opiate substitution 
therapy, high-coverage needle and 
syringe exchange programs and 
HCV treatment on chronic 
prevalence and incidence 
Compartmental model/ 
deterministic differential equations  
 
HCV treatment is necessary to achieve a large 
reduction (>45%) in HCV chronic prevalence 
over 10 years. 
 
Opiate substitution therapy, high-coverage needle 
and syringe exchange programs and new direct-
acting antivirals should reduce the number of 
necessary treatments. 
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Reference 
Country 
 
(setting) 
Objectives Model/approach Main results 
Elbasha (49) USA To assess the impact of treatment 
on transmission of HCV in an 
PWID population 
Compartmental model/ 
deterministic differential equations  
 
The incidence can increase or decrease with 
treatment according to the re-infection rate, but 
the prevalence is always lower with treatment 
than without 
Rolls et al. (50) Australia To investigate the effect of the 
number of contacts on time to 
primary infection and the role of 
spontaneously clearing nodes on 
incidence rates; and the effect of 
treatment strategies based on 
networks properties on incidence 
rates of primary infections and 
reinfections 
Individual-based model on a 
simulated contact network of PWID 
/ stochastic approach 
 
The number of contacts and injecting frequency 
play a key role in reducing the time before 
primary infection  
 
The spontaneous clearance has a local effect (i.e. 
around the concerning individual) on infection 
risk and the total number of spontaneous recovery 
has a global effect on the incidence of both 
primary and re-infection rates 
 
Network-based treatment strategies that chose 
PWID and treat their contact are most effective 
and allow to reduce the number of treatment 
needed to achieve a desired effect 
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Figure 1: Identification of the relevant articles. 
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Figure 2: Schematic representation of a compartmental model for the transmission of HCV in 
PWID (57). The model takes into account infectious status, acute hepatitis C, testing, linkage 
to care, loss to follow-up and treatment. We distinguished recently initiated PWID and 
experienced PWID because of their different risk of infection (58). Reinfections are possible, 
but no retreatment is allowed in the model. Transitions occur between the compartments at 
transition rates that can depend on time: the infection rate depends on the current number of 
infected PWID in the population. 
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Figure 3: Main component of an empirical network of PWID in Melbourne from Rolls et al. 
(31). Each node represents a PWID, and a tie is drawn between the injecting partners in the 
previous 3 months. Data courtesy of DA Rolls.  
 
 
 
 
 
 
